Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Sector news Biotechnology & Medical Research - NEC
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
04/12Takeda sounds out banks for loans as it moves towards Shire bid - sources
RE
04/10Novartis Deal to Help Drug Pipeline -- WSJ
DJ
04/10WHAT'S NEWS : Business & Finance -- WSJ
DJ
04/09Gene-Therapy Stocks Get Boost as Analysts Speculate Novartis' Next Target -- ..
DJ
04/09NOVARTIS : Buying AveXis for $8.7 Billion -- Deal Digest
DJ
04/09Novartis bets big on gene therapy with $8.7 billion AveXis deal
RE
04/09Novartis bets big on gene therapy with $8.7 billion AveXis deal
RE
04/09Novartis bets big on gene therapy with $8.7 billion AveXis deal
RE
04/09EUROPE MARKETS : European Stocks Rise To 2-week High
DJ
04/09NOVARTIS : Bets $8.7 Billion on Gene-Therapy Company -- Update
DJ
04/09NOVARTIS : Bets $8.7 Billion on Gene Therapy Company
DJ
04/09Novartis to Buy AveXis for $8.7 Billion -- Update
DJ
04/09NOVARTIS : to Buy AveXis for $8.7 Billion
DJ
04/09AVEXIS : Novartis AG to buy AveXis Inc for $8.7 billion
RE
04/06Incyte Shares Tumble After Cancer Drug Fails in Trial With Merck's Keytruda
DJ
03/21Britain's use of copycat biotech drugs takes off while U.S. lags
RE
03/21GlaxoSmithKline prescribes commercial reboot for pharma division
RE
03/21GlaxoSmithKline prescribes commercial reboot for pharma division
RE
03/11REGENERON PHARMACEUTICALS : and Sanofi Plan to Cut Cholesterol Drug Price in Exc..
DJ
03/10REGENERON PHARMACEUTICALS : and Sanofi Plan to Cut Cholesterol Drug Price in Exc..
DJ
03/10Prisons Expand Hepatitis Treatment -- WSJ
DJ
03/09More Prison Inmates Get Access to Hepatitis-C Drugs
DJ
02/22SANGAMO THERAPEUTICS : Surges on Therapy Collaboration Deal with Kite -- Market ..
DJ
02/22Sangamo in $3 billion gene-editing deal with Gilead
RE
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
02/08FTSE slides after BOE meeting as pound pops higher
RE
02/08REGENERON PHARMACEUTICALS : Collaborations Drive Revenue Increase at Regeneron -..
DJ
02/07GlaxoSmithKline sees light at end of Advair tunnel
RE
02/06GILEAD SCIENCES : Reports Quarterly Loss Driven by Tax Charge -- Earnings Review
DJ
01/30Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom
RE
01/22Biotech M&A takes off as Sanofi and Celgene spend $20 billion
RE
01/22New drugs recast $10 billion haemophilia market as Sanofi swoops in
RE
01/12Drugmakers see a pricing blueprint in an $850,000 gene therapy
RE
01/12SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
RE
01/08$11 billion biotech binge fuels forecasts of 2018 M&A surge
RE
01/08SANOFI : and Regeneron boost investment in cancer drug cemiplimab
RE
01/07ALNYLAM PHARMACEUTICALS : Sanofi Restructure RNAi Rare-Disease Alliance -- Updat..
DJ
01/07ALNYLAM PHARMACEUTICALS : Sanofi Restructure RNAi Rare-Disease Alliance
DJ
01/05Best week since April for European shares as UK, Swiss indexes hit records
RE
01/02New drug approvals hit 21-year high in 2017
RE
2017STOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
DJ
1  2  3  4  5  6  7  8  9  10Next
Financials (€)
Sales 2018 64,5 M
EBIT 2018 -43,8 M
Net income 2018 -60,3 M
Finance 2018 92,1 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 50,6x
EV / Sales 2019 20,0x
Capitalization 3 353 M
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
ABLYNX114.77%4 150
CELLTRION, INC.--.--%33 565
IQVIA HOLDINGS INC0.92%20 671
LONZA GROUP-8.28%18 519
NEKTAR THERAPEUTICS56.92%14 892
INCYTE CORPORATION-25.54%14 841
ALNYLAM PHARMACEUTICALS, INC.-22.59%9 787
SEATTLE GENETICS, INC.-3.33%8 033
SAGE THERAPEUTICS INC4.69%7 894
QIAGEN6.72%7 636
ALKERMES PLC-15.29%7 315
ICON PLC8.09%6 551
EXACT SCIENCES CORPORATION-9.25%5 781
IONIS PHARMACEUTICALS INC-11.55%5 774
BIO-TECHNE CORP18.11%5 747
PRA HEALTH SCIENCES INC-2.70%5 642
CHARLES RIVER LABORATORIES INTL. INC-1.32%5 184
GALAPAGOS-0.89%4 963
UNITED THERAPEUTICS CORPORATION-22.89%4 851
HANGZHOU TIGERMED CONSULTING CO LTD--.--%4 390
SYNEOS HEALTH INC-11.24%4 037